We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
-7.5%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$423M
AUM Growth
-$75.9M
Cap. Flow
-$12.4M
Cap. Flow %
-2.92%
Top 10 Hldgs %
80.15%
Holding
23
New
1
Increased
4
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$16.5M
2
LOXO
Loxo Oncology, Inc
LOXO
+$5.79M
3
XENT
Intersect ENT, Inc
XENT
+$1.57M
4
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$174K
5
CDTX
Cidara Therapeutics
CDTX
+$20.3K

Top Sells

Rank Stock Value
1
DERM
Dermira, Inc.
DERM
+$24M
2
CTLT
CATALENT, INC.
CTLT
+$6.4M
3
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$2.94M
4
AGRX
Agile Therapeutics
AGRX
+$2.74M
5
ROKA
Sorrento Tech, Inc. Common Stock
ROKA
+$354K

Sector Composition

Rank Sector Weight
1 Healthcare 68.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$93.4M 22.05%
4,028,920
+232,558
+6% +$5.79M
ZLTQ
2
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$57.7M 13.62%
2,109,727
+6,199
+0.3% +$174K
AIMT
3
DELISTED
Aimmune Therapeutics
AIMT
$32.4M 7.64%
2,990,000
– –
VRAY
4
DELISTED
ViewRay, Inc.
VRAY
$30.5M 7.21%
7,461,923
– –
ARAV
5
DELISTED
Aravive, Inc. Common Stock
ARAV
$25.2M 5.95%
379,928
– –
TTOO
6
DELISTED
T2 Biosystems, Inc
TTOO
$22.3M 5.28%
566
– –
ADMA icon
7
ADMA Biologics
ADMA
$2.03B
$21.5M 5.07%
3,608,171
– –
CEMP
8
DELISTED
Cempra, Inc.
CEMP
$19.7M 4.65%
1,193,060
– –
AGRX
9
DELISTED
Agile Therapeutics
AGRX
$19.7M 4.64%
1,292
-200
-13% -$2.74M
CYNA
10
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$17.1M 4.04%
1,021,381
– –
SYRS
11
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$16.5M 3.89%
+90,857
New +$16.5M
ESPR
12
DELISTED
Esperion Therapeutics
ESPR
$16.2M 3.82%
1,637,125
– –
CTLT
13
DELISTED
CATALENT, INC.
CTLT
$10.9M 2.57%
472,781
-242,892
-34% -$6.4M
CDTX
14
DELISTED
Cidara Therapeutics
CDTX
$10.5M 2.49%
51,057
+84
+0.2% +$20.3K
ASXC
15
DELISTED
Asensus Surgical, Inc.
ASXC
$10.2M 2.4%
641,217
– –
PRTK
16
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$6.71M 1.59%
482,680
-200,000
-29% -$2.94M
XENT
17
DELISTED
Intersect ENT, Inc
XENT
$5.82M 1.37%
450,000
+100,000
+29% +$1.57M
DERM
18
DELISTED
Dermira, Inc.
DERM
$3M 0.71%
102,593
-868,230
-89% -$24M
CMRX
19
DELISTED
Chimerix, Inc.
CMRX
$1.86M 0.44%
472,943
– –
EVAR
20
DELISTED
Lombard Medical, Inc.
EVAR
$966K 0.23%
886,363
– –
PTX
21
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$905K 0.21%
201,000
– –
ROKA
22
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
– –
-51,292
Closed -$354K

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Aisling Capital held 23 positions worth $423M, down 15% from $499M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Aisling Capital's Q2 2016 filing shows 1 new, 4 increased, 4 reduced and 1 closed positions. Its largest new stake was Syros Pharmaceuticals, Inc. Common Stock: 90,857 shares worth $16.5M. The largest sale was Dermira, Inc., an estimated $24M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 68% a quarter earlier.

  • Aisling Capital's largest Q2 2016 buy was Syros Pharmaceuticals, Inc. Common Stock: 90,857 shares worth $16.5M.
  • Aisling Capital added most to Loxo Oncology, Inc in Q2 2016, an estimated $5.79M increase.
  • Aisling Capital's biggest Q2 2016 reduction was Dermira, Inc., cutting an estimated $24M.
  • Aisling Capital fully exited Sorrento Tech, Inc. Common Stock in Q2 2016, selling an estimated $354K.
  • Aisling Capital's ten largest holdings make up 80% of its $423M portfolio in Q2 2016.
  • Aisling Capital opened 1 new position and closed 1 in Q2 2016.
  • Aisling Capital's portfolio value fell 15% quarter-over-quarter to $423M.

Based on Aisling Capital's 13F filing for Q2 2016, filed 12 Aug 2016.